The Three Stocks Winning Alongside The GME Squeeze

This morning GameStop Corp. (GME) has been on fire as Roaring Kitty has returned. Stocks like Koss Corporation (KOSS), BlackBerry Limited (BB) and most notably AMC Entertainment Holdings, Inc. (AMC) are up in sympathy, though they have given up a lot of their gains. 

What people need to realize is that short squeezes are all connected. There are three stocks right now that are moving up as part of the GME squeeze that are under-the-radar but are certainly correlated.

The first and most obvious one is ImmunityBio, Inc. (IBRX). It was quiet at first, but shortly after GME broke $30, it moved 5% to around $8.50 and sits near its day high at the time of this write up. 








When we compare the stats of GME to IBRX, they are very similar, with IBRX having a slight advantage.

As the shorts capitulate on GME, look for IBRX to follow.

The second one is Dave Inc. (DAVE), which has a very similar 5% spike once GME broke $30:









DAVE last week had strong earnings which drove the stock price up and has a CVNA-like chart. The stock has 700,000 shorts on a 7 million float. This is like a "KOSS" play. Lower short interest, but because the volume and float is so small, it has as good of a chance for a wild spike as anything. 

Third is Innodata Inc. (INOD), which like the other two, has a spike once GME broke $30:










Like DAVE, it has very strong earnings which lifted it up last week, and shorts are in a bind. There are 3.6 million shares short on a 27 million float for a 13% short interest. 

The correlation between all three of these stocks once GME broke $30 is key. Shorts are getting a beat down today. These three stocks have a chance to benefit with a massive run like GME has had. 

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more